Head to Head Analysis: Helius Medical Technologies (OTCMKTS:HSDT) and Soleno Therapeutics (OTCMKTS:SLNO) – Riverton Roll

Helius Medical Technologies (OTCMKTS:HSDT) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Helius Medical Technologies and Soleno Therapeutics net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Helius Medical Technologies and Soleno Therapeutics top-line revenue, earnings per share and valuation.

Helius Medical Technologies has higher earnings, but lower revenue than Soleno Therapeutics.

Insider and Institutional Ownership

32.4% of Soleno Therapeutics shares are held by institutional investors. 23.0% of Helius Medical Technologies shares are held by insiders. Comparatively, 26.6% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Helius Medical Technologies and Soleno Therapeutics, as provided by MarketBeat.

Helius Medical Technologies currently has a consensus price target of $12.00, suggesting a potential upside of 2,207.69%. Soleno Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 333.53%. Given Helius Medical Technologies higher probable upside, equities analysts plainly believe Helius Medical Technologies is more favorable than Soleno Therapeutics.

Summary

Soleno Therapeutics beats Helius Medical Technologies on 5 of the 8 factors compared between the two stocks.

About Helius Medical Technologies

Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brains ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brains ability to compensate for damage due to trauma or disease. The Companys PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.

About Soleno Therapeutics

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:

Head to Head Analysis: Helius Medical Technologies (OTCMKTS:HSDT) and Soleno Therapeutics (OTCMKTS:SLNO) - Riverton Roll